Karus Therapeutics Appoints Penelope Ward as CMO

Oxford, UK, 12 November 2013 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced that Penelope Ward has joined the Company in the role of Chief Medical Officer. Her appointment strengthens the Company’s expansion which recently saw the formation of a Scientific Advisory […]

Karus Therapeutics wins ‘Best Biotech Fundraiser’ award

Oxford, UK, 2 October 2013 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has won ‘Best Biotech Fundraiser’ at this year’s OBN Awards ahead of shortlisted candidates e-Therapeutics and Heptares Therapeutics. The accolade recognised the progress Karus has made in securing US$7 (~£5m) million […]

Karus Therapeutics shortlisted for key industry award

Oxford, UK, 26 September 2013 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, is shortlisted for the ‘Best Biotech Fundraiser’ at this year’s OBN Awards. The awards will be held on the 1st October 2013 at the Ashmolean Museum in Oxford and will bring […]

Karus Therapeutics secures prominent role in epigenetics debate at SciBX Summit 2013

Oxford, UK, 21 August 2013 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced its engagement with the “Epigenetics’ Second Wind” debate at the SciBX Summit on Innovation in Drug Discovery and Development to be held in Boston, USA, on 29-30 October. Karus […]

Karus Therapeutics interviewed by Pharma Television

Oxford, UK, 17 July 2013 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, was interviewed about its pioneering work in the HDAC and PI3K arena. Dr Simon Kerry, Karus’s CEO discussed the Company’s plans to develop current programmes using its substantial financing backing with […]

Karus Therapeutics features on BBC South News

Oxford, UK, 15 May 2013 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, was featured on BBC South Today to highlight the importance of attracting venture capital financing to support the research and development of early stage biotechnology companies in the Oxfordshire area. The […]

Karus Therapeutics presenting at BIO, BioTrinity, Anglo-Nordic Biotech and Next-Gen Kinase Inhibitors

Oxford, UK, 19 April 2013 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be making presentations at a number of key trade conferences including: BIO International Convention, Chicago, USA, 22-25th April: Simon Kerry, CEO, will present at the conference’s BIO […]

Karus Therapeutics appoints Scientific Advisory Board and announces move to new Oxford facilities

Oxford, UK, 9 April 2013 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced the appointment of its scientific advisory board (SAB), which brings together world-leading expertise in target biology and drug research and development. The appointment of Karus’s SAB reflects the Company’s […]